Novo Nordisk

Thumbnail for Novo Nordisk invests US$1.2 B in new production facility in Odense, Denmark

16 December 2024

Novo Nordisk invests US$1.2 B in new production facility in Odense, Denmark

Thumbnail for Ypsomed to supply pens for Novo Nordisk’s CagriSema

22 November 2024

Ypsomed to supply pens for Novo Nordisk’s CagriSema

Thumbnail for NanoVation secures funding, expands board

21 November 2024

NanoVation secures funding, expands board

Thumbnail for Novo Nordisk’s Semaglutide shows promise in treating liver disease

20 November 2024

Novo Nordisk’s Semaglutide shows promise in treating liver disease

Thumbnail for Sahpra warns of counterfeit diabetes drugs in South Africa

13 November 2024

Sahpra warns of counterfeit diabetes drugs in South Africa

Thumbnail for Novo Nordisk leverages Ascendis’ tech for Next-Gen diabetes drug

7 November 2024

Novo Nordisk leverages Ascendis’ tech for Next-Gen diabetes drug

Thumbnail for Novo Nordisk’s ESSENCE trial shows promising results for semaglutide 2.4 mg in treating MASH

4 November 2024

Novo Nordisk’s ESSENCE trial shows promising results for semaglutide 2.4 mg in treating MASH

Thumbnail for Novo Nordisk’s Alhemo® receives positive opinion from EMA for haemophilia treatment

22 October 2024

Novo Nordisk’s Alhemo® receives positive opinion from EMA for haemophilia treatment

Thumbnail for Novo Nordisk launches global initiative to combat childhood obesity

9 October 2024

Novo Nordisk launches global initiative to combat childhood obesity

Thumbnail for Novo Nordisk advances Wegovy label, expands genetic medicine portfolio with NanoVation partnership

20 September 2024

Novo Nordisk advances Wegovy label, expands genetic medicine portfolio with NanoVation partnership